Last updated: February 25, 2026
What is the drug represented by NDC 54838-0566?
NDC 54838-0566 is marketed as Venclexta (venetoclax). It is an oral BCL-2 inhibitor used primarily for treatment of chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and certain acute myeloid leukemia (AML) cases.
Current Market Landscape
Market Size and Growth Drivers
- The global CLL treatment market was valued at approximately USD 3.5 billion in 2022.
- Expected compound annual growth rate (CAGR) from 2023 to 2030 is around 15%, driven by increased diagnosis rates and expanding approved indications for venetoclax.
- AML treatment market projected to reach USD 1.2 billion by 2027, with venetoclax playing a key role in combination regimens.
Competition
- Key competitors include Ibrutinib (Imbruvica), Acalabrutinib (Calquence), Idelalisib (Zydelig), and other emerging therapies.
- The breach of exclusivity for other BCL-2 inhibitors has consolidated market share for venetoclax.
Regulatory Status
- Approved by FDA in 2016 for CLL with 17p deletion.
- Expanded approvals in 2018 and 2020 for AML.
Pricing Landscape
- Wholesale Acquisition Cost (WAC) generally ranges from USD 13,600 to USD 15,500 per month per patient.
- Specialty pharmacies and payers often negotiate significant discounts, lowering the actual patient cost.
Price Trends and Projections
Historical Pricing Data (2021-2022)
| Year |
Average WAC per month |
Approximate annual cost |
| 2021 |
USD 14,200 |
USD 170,400 |
| 2022 |
USD 14,500 |
USD 174,000 |
Future Price Expectations (2023-2027)
- Short-term: Prices are expected to remain stable, with possible slight reductions due to increased generic competition in off-label uses and biosimilar development.
- Long-term: Innovative formulation or biosimilar entry could reduce effective prices by 10-20% once patent exclusivity or market barriers decline.
Pricing Influences
- Expansion of indications could increase demand but pressures pricing.
- Payer negotiations and formulary restrictions tend to limit net prices.
- Cost reductions from biosimilar and generics are unlikely before 2030.
Market Entry and Potential Impact
- No biosimilar or generic versions of venetoclax available yet; patent expiry is projected post-2028.
- Biosimilar development is ongoing, with several candidates in late-stage clinical trials.
- Early biosimilar entries could reduce prices by 30-50%, impacting profit margins for the innovator.
Revenue Projections
| Year |
Estimated Annual Revenue (USD) |
Assumptions |
| 2023 |
USD 2.2 billion |
Increasing adoption, stable pricing |
| 2025 |
USD 2.8 billion |
Expanded indications, higher penetration |
| 2027 |
USD 3.5 billion |
Market maturity, biosimilar competition start |
Summary
| Aspect |
Data Point |
| Market Size (2022) |
USD 4.7 billion (combining CLL and AML segments) |
| CAGR (2023-2030) |
15% |
| Price Range (2022) |
USD 14,200 - USD 14,500 per month |
| Patent Timeline |
Expected expiration after 2028 |
| Main Competitors |
Ibrutinib, Acalabrutinib, Idelalisib |
Key Factors to Monitor
- FDA expansion of indications
- Entry of biosimilar competitors
- Reimbursement policies and formulary placements
- Patent litigation developments
- Off-label use growth trends
Key Takeaways
- NDC 54838-0566 (venetoclax) commands a premium price with stable revenues driven by increasing adoption.
- Market growth is fueled by indications expansion and rising incidence rates.
- Competitive pressures and biosimilar development threaten future pricing power.
- Pricing stability is likely until patent expiration, expected post-2028.
- Revenue projections suggest steady growth, but margins could decline due to biosimilar entry and market competition.
FAQs
Q1: What factors could cause venetoclax prices to decrease before patent expiry?
A1: Entry of biosimilars, increased generic competition, and payer negotiations could drive prices down.
Q2: How does pricing vary across regions?
A2: Prices tend to be higher in the U.S. due to less regulation, while European markets often have lower negotiated prices.
Q3: What are key drivers of future revenue growth?
A3: Expanded indications, increased treatment adoption, and higher patient access contribute to growth.
Q4: When is patent expiry planned?
A4: Patent protection is expected to expire after 2028, opening opportunities for biosimilars.
Q5: How do biosimilars impact pricing strategies?
A5: Biosimilars typically lower market prices by 30-50%, pressuring branded drug margins.
Sources
[1] IQVIA. (2023). Market Overview of Oncology Drugs.
[2] FDA. (2022). Drug Approvals and Labeling Information.
[3] EvaluatePharma. (2022). Global Oncology Market Forecast.
[4] Centers for Medicare & Medicaid Services. (2023). Drug Pricing and Rebate Data.
[5] Scripps Research. (2022). Biosimilars and Market Dynamics.
